{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T21:00:02Z","timestamp":1781730002658,"version":"3.54.5"},"reference-count":53,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.vaccine.2022.08.052","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:21:50Z","timestamp":1663806110000},"page":"6163-6178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Serological responses to Anthrax Vaccine Precipitated (AVP) increase with time interval between booster doses"],"prefix":"10.1016","volume":"40","author":[{"given":"E. Hugh","family":"Dyson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.H.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Gwyther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Cuthbertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn H.","family":"Patient","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Matheson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anya","family":"Gregg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Hepburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassam","family":"Hallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Diane","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.08.052_b0005","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1001\/jama.287.17.2236","article-title":"Anthrax as a biological weapon: updated recommendations for management","volume":"287","author":"Inglesby","year":"2002","journal-title":"JAMA"},{"issue":"44","key":"10.1016\/j.vaccine.2022.08.052_b0010","doi-asserted-by":"crossref","first-page":"7641","DOI":"10.1016\/j.vaccine.2007.08.065","article-title":"Anthrax vaccination in a military population before the war in Iraq: side effects and informed choice","volume":"25","author":"Murphy","year":"2007","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2022.08.052_b0015","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.vaccine.2011.12.030","article-title":"A longitudinal study of UK military personnel offered anthrax vaccination: informed choice, symptom reporting, uptake and pre-vaccination health","volume":"30","author":"Murphy","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.08.052_b0020","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/pds.936","article-title":"Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS)","volume":"13","author":"Sever","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2022.08.052_b0025","doi-asserted-by":"crossref","unstructured":"Friedlander AM, Grabenstein JD, Brachman PS. Anthrax vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. Philadelphia: Elsevier Saunders; 2013. p. 127\u201340 [Chap 10]. ISBN-13: 9781455737987.","DOI":"10.1016\/B978-1-4557-0090-5.00022-7"},{"key":"10.1016\/j.vaccine.2022.08.052_b0030","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.1016\/j.vaccine.2007.05.018","article-title":"Immune response to two different dosing schedules of the anthrax vaccine precipitated (AVP) vaccine","volume":"25","author":"Hepburn","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.08.052_b0035","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0264-410X(01)00462-5","article-title":"Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans","volume":"20","author":"Pittman","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.08.052_b0040","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1172\/JCI0216204","article-title":"Development of an improved vaccine for anthrax","volume":"110","author":"Leppla","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2022.08.052_b0045","unstructured":"FDA anthrax vaccination guidance. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/biothrax."},{"key":"10.1016\/j.vaccine.2022.08.052_b0050","unstructured":"BioThrax PIL (Europe). Available from: https:\/\/www.emergentbiosolutions.com\/wp-content\/uploads\/2022\/01\/BioThrax-Information-Summary-Product-Characteristics-Common-2.pdf."},{"key":"10.1016\/j.vaccine.2022.08.052_b0055","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0014-5793(02)03609-8","article-title":"Anthrax toxin: a tripartite lethal combination","volume":"531","author":"Ascenzi","year":"2002","journal-title":"FEBS Lett"},{"issue":"6","key":"10.1016\/j.vaccine.2022.08.052_b0060","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1128\/CVI.00513-09","article-title":"Comparison of three anthrax toxin neutralization assays","volume":"17","author":"Ngundi","year":"2010","journal-title":"Clin Vacc Immunol"},{"key":"10.1016\/j.vaccine.2022.08.052_b0065","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0882-4010(88)90015-0","article-title":"Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice","volume":"5","author":"Welkos","year":"1988","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2022.08.052_b0070","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1365-2672.1999.00897.x","article-title":"In vitro correlate of immunity in an animal model of inhalational anthrax","volume":"87","author":"Pitt","year":"1999","journal-title":"J Appl Microbiol"},{"key":"10.1016\/j.vaccine.2022.08.052_b0075","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1016\/S0264-410X(01)00234-1","article-title":"In vitro correlate of immunity in a rabbit model of inhalational anthrax","volume":"19","author":"Pitt","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.08.052_b0080","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1099\/00221287-147-6-1677","article-title":"The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores","volume":"147","author":"Welkos","year":"2001","journal-title":"Microbiology"},{"key":"10.1016\/j.vaccine.2022.08.052_b0085","doi-asserted-by":"crossref","unstructured":"Saile E, Quinn CP. Anthrax vaccines. In: Bergman NH, editor. Bacillus anthracis and anthrax. Wiley-Blackwell; 2011. p. 269\u201393 [Chap 14]. ISBN 978-0-470-41011-0.","DOI":"10.1002\/9780470891193.ch14"},{"key":"10.1016\/j.vaccine.2022.08.052_b0090","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.femsim.2004.05.011","article-title":"Characterization of the human immune response to the UK anthrax vaccine","volume":"42","author":"Baillie","year":"2004","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"7","key":"10.1016\/j.vaccine.2022.08.052_b0095","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1128\/IAI.69.7.4509-4515.2001","article-title":"Protection against anthrax lethal toxin challenge by genetic immunisation with a plasmid encoding the lethal factor protein","volume":"69","author":"Price","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2022.08.052_b0100","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.vaccine.2003.09.043","article-title":"Genetic immunization against anthrax","volume":"22","author":"Galloway","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.08.052_b0105","unstructured":"Green Book, Chapter 13: Anthrax. Immunisation against infectious disease. Public Health England; 2013. Available from: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/147832\/Green-Book-updated-140313.pdf"},{"key":"10.1016\/j.vaccine.2022.08.052_b0110","unstructured":"Green Book, Chapter 13: Anthrax (Version 2). Immunisation against infectious disease. Public Health England; 2017. Available from: https:\/\/www.gov.uk\/government\/publications\/anthrax-the-green-book-chapter-13."},{"issue":"39","key":"10.1016\/j.vaccine.2022.08.052_b0115","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1016\/j.vaccine.2014.03.076","article-title":"Anthrax vaccine adsorbed: further evidence supporting continuing the vaccination series rather than restarting the series when doses are delayed","volume":"32","author":"Pittman","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.08.052_b0120","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.4049\/jimmunol.0901581","article-title":"Natural exposure to cutaneous anthrax gives long-lasting T cell immunity encompassing infection-specific epitopes","volume":"184","author":"Ingram","year":"2010","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2022.08.052_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148713","article-title":"A comparison of the adaptive immune response between recovered anthrax patients and individuals receiving three different anthrax vaccines","volume":"11","author":"Laws","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2022.08.052_b0130","unstructured":"Turnbull PC. WHO guidance: anthrax in humans and animals. 4th ed.; 2008. Available from: apps.who.int\/iris\/bitstream\/handle\/10665\/97503\/9789241547536_eng.pdf;jsessionid=7946E754137C092CAE156658C87C8760?sequence=1"},{"issue":"3","key":"10.1016\/j.vaccine.2022.08.052_b0135","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/21645515.2020.1799668","article-title":"Characterization of the UK anthrax vaccine and human immunogenicity","volume":"17","author":"Modi","year":"2021","journal-title":"Hum Vacc Immunother"},{"issue":"26","key":"10.1016\/j.vaccine.2022.08.052_b0140","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1016\/j.vaccine.2017.05.006","article-title":"Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated","volume":"35","author":"Dumas","year":"2017","journal-title":"Vaccine"},{"issue":"41","key":"10.1016\/j.vaccine.2022.08.052_b0145","doi-asserted-by":"crossref","first-page":"21596","DOI":"10.1074\/jbc.M116.749184","article-title":"A diverse set of single-domain antibodies (VHHs) against the anthrax toxin Lethal and Edema Factors provides a basis for construction of a bispecific agent that protects against anthrax infection","volume":"291","author":"Vrentas","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2022.08.052_b0150","doi-asserted-by":"crossref","unstructured":"Dumas EK, Demiraslan H, Ingram RJ, Sparks RM, Muns E, Zamora A, et al. Toxin neutralizing antibodies elicited by naturally acquired cutaneous anthrax are elevated following severe disease and appear to target conformational epitopes. PLoS ONE 2020;15(4):e0230782. doi: 10.1371\/journal.pone.0230782.","DOI":"10.1371\/journal.pone.0230782"},{"key":"10.1016\/j.vaccine.2022.08.052_b0155","doi-asserted-by":"crossref","first-page":"e00165","DOI":"10.1128\/CVI.00165-17","article-title":"Anthrax vaccine precipitated induces edema toxin-neutralizing, edema factor-specific antibodies in human recipients","volume":"24","author":"Dumas","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2022.08.052_b0160","doi-asserted-by":"crossref","unstructured":"Baldwin VM. You can\u2019t B. cereus \u2013 a review of Bacillus cereus strains that cause anthrax-like disease. Front Microbiol 2020;11:1731. doi: 10.3389\/fmicb.2020.01731.","DOI":"10.3389\/fmicb.2020.01731"},{"key":"10.1016\/j.vaccine.2022.08.052_b0165","unstructured":"FDA review of safety and efficacy of BioThrax. Available from: https:\/\/www.federalregister.gov\/documents\/2005\/12\/19\/05-24223\/biological-products-bacterial-vaccines-and-toxoids-implementation-of-efficacy-review-anthrax-vaccine."},{"key":"10.1016\/j.vaccine.2022.08.052_b0170","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2105\/AJPH.52.4.632","article-title":"Field evaluation of a human anthrax vaccine","volume":"52","author":"Brachman","year":"1962","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2022.08.052_b0175","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(56)91968-7","article-title":"The use of anthrax antigen to immunize man and monkey","volume":"268","author":"Darlow","year":"1956","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.08.052_b0180","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S0140-6736(69)90130-5","article-title":"Serological diagnosis of anthrax","volume":"294","author":"Darlow","year":"1969","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.08.052_b0185","unstructured":"CDSC. Anthrax surveillance 1961\u201380. PHLS communicable disease report 1981, 81\/46; 1981."},{"key":"10.1016\/j.vaccine.2022.08.052_b0190","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1183\/09031936.00201112","article-title":"Inhalational anthrax in a vaccinated soldier","volume":"42","author":"Sykes","year":"2013","journal-title":"Eur Respir J"},{"issue":"22","key":"10.1016\/j.vaccine.2022.08.052_b0195","doi-asserted-by":"crossref","first-page":"8449","DOI":"10.1073\/pnas.0402414101","article-title":"Identification of anthrax toxin genes in a Bacillus cereus associated with an illness resembling inhalation anthrax","volume":"101","author":"Hoffmaster","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"10.1016\/j.vaccine.2022.08.052_b0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004923","article-title":"Bacillus cereus Biovar Anthracis Causing Anthrax in Sub-Saharan Africa\u2014Chromosomal Monophyly and Broad Geographic Distribution","volume":"10","author":"Antonation","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2022.08.052_b0205","unstructured":"Public Health England (PHE). Human anthrax in England and Wales; 2012 (archived 14 July 2014). Available from: http:\/\/webarchive.nationalarchives.gov.uk\/20140714084352\/http:\/\/www.hpa.org.uk\/Topics\/InfectiousDiseases\/InfectionsAZ\/Anthrax\/EpidemiologicalData\/."},{"key":"10.1016\/j.vaccine.2022.08.052_b0210","doi-asserted-by":"crossref","unstructured":"Anaraki S, Addiman S, Nixon G, Krah\u00e9 D, Ghosh R, Brooks T, et al. Investigations and control measures following a case of inhalation anthrax in East London in a drum maker and drummer, October 2008. Eurosurveillance 2008;13(51):pii=19076. doi: 10.2807\/ese.13.51.19076-en.","DOI":"10.2807\/ese.13.51.19076-en"},{"issue":"5","key":"10.1016\/j.vaccine.2022.08.052_b0215","doi-asserted-by":"crossref","DOI":"10.1099\/mgen.0.000039","article-title":"Whole-genome sequencing investigation of animal-skin-drum-associated UK anthrax cases reveals evidence of mixed populations and relatedness to a US case","volume":"1","author":"Pullan","year":"2015","journal-title":"Microb Genomics"},{"key":"10.1016\/j.vaccine.2022.08.052_b0220","doi-asserted-by":"crossref","unstructured":"Grunow R, Klee SR, Beyer W, George M, Grunow D, Barduhn A, et al. Anthrax among heroin users in Europe possibly caused by same Bacillus anthracis strain since 2000. Eurosurveillance 2013;18(13):pii=20437. doi: 10.2807\/ese.18.13.20437-en.","DOI":"10.2807\/ese.18.13.20437-en"},{"key":"10.1016\/j.vaccine.2022.08.052_b0225","unstructured":"BMJ Best Practice Guidelines on Anthrax: Epidemiology 18 June 2015. Available from: http:\/\/bestpractice.bmj.com\/best-practice\/monograph\/604\/basics\/epidemiology.html."},{"key":"10.1016\/j.vaccine.2022.08.052_b0230","unstructured":"HPA information on IDU anthrax outbreak in UK 2012-13: Available from: https:\/\/webarchive.nationalarchives.gov.uk\/ukgwa\/20140714091607\/http:\/\/www.hpa.org.uk\/webw\/HPAweb&HPAwebStandard\/HPAweb_C\/1317138327693"},{"key":"10.1016\/j.vaccine.2022.08.052_b0235","unstructured":"HSE anthrax advice datasheet; 2021. Available from: https:\/\/www.hse.gov.uk\/agriculture\/zoonoses-data-sheets\/anthrax.pdf."},{"key":"10.1016\/j.vaccine.2022.08.052_b0240","unstructured":"HSE guidance on Anthrax: Safe working and the Prevention of Infection; 1997. Available from: https:\/\/cedrec.com\/cedrec_images\/upload\/guidance\/hsg174.pdf"},{"key":"10.1016\/j.vaccine.2022.08.052_b0245","unstructured":"Centers for Disease Control and Prevention. Suspected cutaneous anthrax in a laboratory worker - Texas, 2002. MMWR 2002;51(13):279\u201381. MMWR 5 April 2002."},{"issue":"2","key":"10.1016\/j.vaccine.2022.08.052_b0250","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1089\/vbz.2008.0032","article-title":"Human anthrax in Turkey from 1990 to 2007","volume":"9","author":"Doganay","year":"2009","journal-title":"Vector Borne Zoonotic Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2022.08.052_b0255","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1017\/S0950268811001488","article-title":"anthracis in a wool-processing factory: seroprevalence and occupational risk","volume":"140","author":"Kissling","year":"2012","journal-title":"Epidemiol Infect"},{"issue":"1","key":"10.1016\/j.vaccine.2022.08.052_b0260","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3201\/eid1001.030238","article-title":"Bacillus anthracis bioterrorism incident, Kameido, Tokyo, 1993","volume":"10","author":"Takashi","year":"2004","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2022.08.052_b0265","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3201\/eid0810.020353","article-title":"Investigation of Bioterrorism-Related Anthrax, United States, 2001: Epidemiologic Findings","volume":"8","author":"Jernigan","year":"2002","journal-title":"Emerg Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22010453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22010453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:18:40Z","timestamp":1759403920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22010453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":53,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0264410X22010453"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.08.052","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serological responses to Anthrax Vaccine Precipitated (AVP) increase with time interval between booster doses","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.08.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}